FREENOME LAUNCHES THE VALLANIA STUDY FOR THE EARLY DETECTION OF MULTIPLE CANCERS

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 /PRNewswire/ -- Freenome, a privately held biotech company, today announced the initiation of Vallania, a clinical study for the refinement and further development of its multiomics platform to detect multiple cancers. The platform uses a routine...

Click to view original post